NPM1 and acute myeloid leukemia: Therefore, she was treated with venetoclax/azacitidine, a regimen with minimal nonhematopoietic toxicity and low DNA damage potential known to induce high remission rates in NPM1-mutated AML, before a second RIC HSCT.